- Home
- BTO vs VALN Comparison
BTO vs VALN Comparison
Compare BTO & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTO
- VALN
- Stock Information
- Founded
- BTO 1994
- VALN 2012
- Country
- BTO United States
- VALN France
- Employees
- BTO N/A
- VALN N/A
- Industry
- BTO Investment Managers
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTO Finance
- VALN Health Care
- Exchange
- BTO Nasdaq
- VALN Nasdaq
- Market Cap
- BTO 670.7M
- VALN 669.2M
- IPO Year
- BTO N/A
- VALN 2021
- Fundamental
- Price
- BTO $35.46
- VALN $11.53
- Analyst Decision
- BTO
- VALN Strong Buy
- Analyst Count
- BTO 0
- VALN 3
- Target Price
- BTO N/A
- VALN $15.33
- AVG Volume (30 Days)
- BTO 54.2K
- VALN 96.9K
- Earning Date
- BTO 01-01-0001
- VALN 08-12-2025
- Dividend Yield
- BTO 9.13%
- VALN N/A
- EPS Growth
- BTO N/A
- VALN N/A
- EPS
- BTO N/A
- VALN N/A
- Revenue
- BTO N/A
- VALN $230,566,060.00
- Revenue This Year
- BTO N/A
- VALN $18.61
- Revenue Next Year
- BTO N/A
- VALN $25.07
- P/E Ratio
- BTO N/A
- VALN N/A
- Revenue Growth
- BTO N/A
- VALN 25.47
- 52 Week Low
- BTO $22.95
- VALN $3.62
- 52 Week High
- BTO $32.81
- VALN $11.53
- Technical
- Relative Strength Index (RSI)
- BTO 53.00
- VALN 77.09
- Support Level
- BTO $35.28
- VALN $10.11
- Resistance Level
- BTO $36.15
- VALN $11.18
- Average True Range (ATR)
- BTO 0.65
- VALN 0.41
- MACD
- BTO 0.07
- VALN 0.35
- Stochastic Oscillator
- BTO 66.82
- VALN 100.00
About BTO John Hancock Financial Opportunities Fund
John Hancock Financial Opportunities Fund is the United States based closed-end, diversified management investment company. Its investment objective is to provide a high level of total return consisting of long-term capital appreciation and current income. The company invests in banks, capital markets, Insurance, Mortage Real Estate Investment trust, Health Care REITs, Diversified REITs, Office REITs.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.